Similar articles for PMID: 22378158

Year	Number of Results
1999	1
2005	1
2006	1
2009	2
2010	2
2011	5
2012	11
2013	17
2014	19
2015	13
2016	3
2017	5
2018	1
2024	0

1

Drug-induced PML: a global agenda for a global challenge.

Vinhas de Souza M, Keller-Stanislawski B, Blake K, Hidalgo-Simon A, Arlett P, Dal Pan G. Vinhas de Souza M, et al. Clin Pharmacol Ther. 2012 Apr;91(4):747-50. doi: 10.1038/clpt.2012.4. Epub 2012 Feb 29. Clin Pharmacol Ther. 2012. PMID: 22378158

2

[Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].

Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP. Soilu-Hänninen M, et al. Duodecim. 2013;129(7):765-70. Duodecim. 2013. PMID: 23720945 Finnish.

3

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C. Bloomgren G, et al. N Engl J Med. 2012 May 17;366(20):1870-80. doi: 10.1056/NEJMoa1107829. N Engl J Med. 2012. PMID: 22591293 Free article.

4

Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.

Anton R, Haas M, Arlett P, Weise M, Balabanov P, Mazzaglia G, Prieto L, Keller-Stanislawski B, Raine J. Anton R, et al. Clin Pharmacol Ther. 2017 Aug;102(2):283-289. doi: 10.1002/cpt.604. Epub 2017 Jan 23. Clin Pharmacol Ther. 2017. PMID: 28001298 Review.

5

[Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy].

Hartung HP, Warnke C, Hohlfeld R, Kieseier BC. Hartung HP, et al. Nervenarzt. 2009 Oct;80(10):1143-4, 1146-8, 1150-3. doi: 10.1007/s00115-009-2701-9. Nervenarzt. 2009. PMID: 19357826 Review. German.

6

Natalizumab: bench to bedside and beyond.

Rudick R, Polman C, Clifford D, Miller D, Steinman L. Rudick R, et al. JAMA Neurol. 2013 Feb;70(2):172-82. doi: 10.1001/jamaneurol.2013.598. JAMA Neurol. 2013. PMID: 23128399 Review.

7

Sorting out the risks in progressive multifocal leukoencephalopathy.

Calabrese LH, Molloy E, Berger J. Calabrese LH, et al. Nat Rev Rheumatol. 2015 Feb;11(2):119-23. doi: 10.1038/nrrheum.2014.167. Epub 2014 Oct 14. Nat Rev Rheumatol. 2015. PMID: 25314016 Review.

8

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.

Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F. Wattjes MP, et al. Mult Scler. 2013 Dec;19(14):1826-40. doi: 10.1177/1352458513510224. Epub 2013 Nov 5. Mult Scler. 2013. PMID: 24192217 Review.

9

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Clifford DB, et al. Lancet Neurol. 2010 Apr;9(4):438-46. doi: 10.1016/S1474-4422(10)70028-4. Lancet Neurol. 2010. PMID: 20298967 Review.

10

Natalizumab-induced progressive multifocal leukoencephalopathy.

Thaker AA, Schmitt SE, Pollard JR, Dubroff JG. Thaker AA, et al. Clin Nucl Med. 2014 Jul;39(7):e365-6. doi: 10.1097/RLU.0000000000000238. Clin Nucl Med. 2014. PMID: 24152618

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

70 results

Results by year